Previous 10 | Next 10 |
HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...
Marker Therapeutics press release ( NASDAQ: MRKR ): Q3 GAAP EPS of -$0.08. Revenue of $3.9M. For further details see: Marker Therapeutics GAAP EPS of -$0.08, revenue of $3.9M
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...
Summary AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials. However, the market doesn't seem interested at present. AlloVir , Inc. ( ALVR ) is a leader in the development of allogeneic, virus-specifi...
Cheap Penny Stocks to Buy For Under $1 If you’re watching the action in the stock market today, you’re seeing plenty of chop. The U.S. dollar’s strength has pushed broader markets lower, but a mix of positive and negative economic against this week’s PPI data...
Marker Therapeutics, Inc. ( NASDAQ: MRKR ), a biotech focused on T cell-based immunotherapies, announced Tuesday that the FDA awarded a $2M grant to support its Phase 2 ARTEMIS trial for liquid tumor candidate MT-401 in patients with post-transplant acute myeloid leukemia (AML...
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today an...
HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, to...
Marker Therapeutics press release ( NASDAQ: MRKR ): Q2 GAAP EPS of -$0.11 misses by $0.01 . Revenue of $0.79M misses by $1.71M . “We are very optimistic about the ability of MT-401 to drive results for patients with measurable residual disease given the ...
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...